Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.
Exciting news out of Washington, DC: the House of Representatives' Energy & Commerce Committee ordered the MD-CARE Act to advance to the House floor!
The DMCRN was established a little over a year ago to evaluate potential DM treatments, prepare possible clinical trial sites and conduct important DM research studies.
An MDF community member describes the MDF Annual Conference and how it has helped her and her family manage this disease and find community.
© Myotonic Dystrophy Foundation. All rights reserved.
Sitemap | User Agreement